Director/PDMR Shareholding
ValiRx PLC announced that Chief Executive Officer Mark Eccleston purchased 1,000,000 ordinary shares at 0.33 pence per share on 3 March 2026. This transaction increases his resultant interest in ordinary shares to 59,746,187, representing 8.04% of the company's issued ordinary shares. This director's shareholding update indicates confidence in the company's future prospects.
Select text to share a quote on X · sign in to keep highlights & notes in your VAL notes
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces that it received notification on 3 March 2026 that Mark Eccleston, Chief Executive Officer, made the following purchase of ordinary shares in the Company.
| Mark Eccleston | 0.33 pence | 1,000,000 | 59,746,187 | 8.04% |
Further details are set out in the Notification of Dealing Form below.
| Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub | https://valirx.com/link/peg6vy | |||||
| ValiRx plc Dr Mark Eccleston, CEO | Tel: +44 115 784 0026 www.valirx.com Mark.Eccleston@valirx.com | |||||
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti | Tel: +44 (0) 20 7213 0880 | |||||
| Shard Capital Partners LLP (Sole Broker) Damon Heath | Tel: +44 (0) 20 7186 9000 | |||||
| V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director | +44 (0) 115 787 0206 www.vformation.biz lucy@vformation.biz sue@vformation.biz | |||||
| Subscribe to our news alert service: https://valirx.com/s/f298d1 | ||||||
| 1 | Details of the persons discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Mark Eccleston | ||||
| 2 | Reason for the notification | |||||
| a) | Position/Status | Chief Executive Officer | ||||
| b) | Initial notification/ Amendment | Initial | ||||
| a) | Name | ValiRx PLC | ||||
| b) | LEI | 213800VQKB9SJCQDET40 | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares GB00BLH13C52 | ||||
| b) | Nature of the transaction | Purchase of shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A | ||||
| e) | Date of transaction | 3 March 2026 | ||||
| f) | Place of transaction | AIM | ||||
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.